FI63409C - Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1,5-dihydro-imidazo(2,1-b)kinazolin-2(3h)-onderivat - Google Patents
Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1,5-dihydro-imidazo(2,1-b)kinazolin-2(3h)-onderivat Download PDFInfo
- Publication number
- FI63409C FI63409C FI782248A FI782248A FI63409C FI 63409 C FI63409 C FI 63409C FI 782248 A FI782248 A FI 782248A FI 782248 A FI782248 A FI 782248A FI 63409 C FI63409 C FI 63409C
- Authority
- FI
- Finland
- Prior art keywords
- quinazolin
- dihydro
- chloro
- formula
- ethyl ester
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 2
- 150000001875 compounds Chemical class 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000007858 starting material Substances 0.000 claims description 6
- XSMVLINRYDTIQZ-MRVPVSSYSA-N ethyl (2r)-2-[(2-amino-6-chlorophenyl)methylamino]propanoate Chemical compound CCOC(=O)[C@@H](C)NCC1=C(N)C=CC=C1Cl XSMVLINRYDTIQZ-MRVPVSSYSA-N 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- YLVVAWCDANPADI-UHFFFAOYSA-N 5,10-dihydro-3h-imidazo[2,1-b]quinazolin-2-one Chemical class C1C2=CC=CC=C2N=C2N1CC(=O)N2 YLVVAWCDANPADI-UHFFFAOYSA-N 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- BHZFZYLBVSWUMT-ZCFIWIBFSA-N quazinone Chemical compound C1=CC=C2NC3=NC(=O)[C@@H](C)N3CC2=C1Cl BHZFZYLBVSWUMT-ZCFIWIBFSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 75
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 235000019441 ethanol Nutrition 0.000 description 25
- 239000000243 solution Substances 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 229910001868 water Inorganic materials 0.000 description 14
- -1 ethanol Chemical compound 0.000 description 13
- 239000013078 crystal Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000012458 free base Substances 0.000 description 8
- 239000000155 melt Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 4
- MKLDLMXFDMZYAD-UHFFFAOYSA-N 1h-quinazolin-2-one;hydrochloride Chemical compound Cl.C1=CC=C2NC(=O)N=CC2=C1 MKLDLMXFDMZYAD-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000007868 Raney catalyst Substances 0.000 description 4
- 229910000564 Raney nickel Inorganic materials 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- BZDIYMXAQMSYMW-MRVPVSSYSA-N ethyl (2r)-2-[(2-chloro-6-nitrophenyl)methylamino]propanoate Chemical compound CCOC(=O)[C@@H](C)NCC1=C(Cl)C=CC=C1[N+]([O-])=O BZDIYMXAQMSYMW-MRVPVSSYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- FHDHUOUALGSAIL-FYZOBXCZSA-N (3R)-7-bromo-3-methyl-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one hydrochloride Chemical compound Cl.C1C2=CC(Br)=CC=C2N=C2N1[C@H](C)C(=O)N2 FHDHUOUALGSAIL-FYZOBXCZSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000001871 Tachycardia Diseases 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 230000004118 muscle contraction Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000006794 tachycardia Effects 0.000 description 3
- KOMRLUDDGJTIRU-FYZOBXCZSA-N (3R)-6-chloro-3-methyl-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one hydrochloride Chemical compound Cl.C1C2=C(Cl)C=CC=C2N=C2N1[C@H](C)C(=O)N2 KOMRLUDDGJTIRU-FYZOBXCZSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DWTVLAFZRWBUGT-UHFFFAOYSA-N CC(O)=O.C1=CC=C2C=NCNC2=C1 Chemical compound CC(O)=O.C1=CC=C2C=NCNC2=C1 DWTVLAFZRWBUGT-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AGUIVNYEYSCPNI-UHFFFAOYSA-N N-methyl-N-picrylnitramine Chemical compound [O-][N+](=O)N(C)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O AGUIVNYEYSCPNI-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- JCXLZWMDXJFOOI-WCCKRBBISA-N ethyl (2s)-2-aminopropanoate;hydrochloride Chemical compound Cl.CCOC(=O)[C@H](C)N JCXLZWMDXJFOOI-WCCKRBBISA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000297 inotrophic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- ZCYROGGVNYNKEX-XFULWGLBSA-N (3R)-3-benzyl-6-chloro-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one hydrochloride Chemical compound Cl.C([C@@H]1C(=O)NC2=NC=3C=CC=C(C=3CN21)Cl)C1=CC=CC=C1 ZCYROGGVNYNKEX-XFULWGLBSA-N 0.000 description 1
- RTJSPGKBNLTHJX-SSDOTTSWSA-N (3R)-3-methyl-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one Chemical compound C1C2=CC=CC=C2N=C2N1[C@H](C)C(=O)N2 RTJSPGKBNLTHJX-SSDOTTSWSA-N 0.000 description 1
- FJWMBWBMHJYEHO-OGFXRTJISA-N (3R)-3-methyl-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one hydrochloride Chemical compound Cl.C1C2=CC=CC=C2N=C2N1[C@H](C)C(=O)N2 FJWMBWBMHJYEHO-OGFXRTJISA-N 0.000 description 1
- HTXRKFKELTXNIG-UTONKHPSSA-N (3R)-6-chloro-3-(2-methylpropyl)-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one hydrochloride Chemical compound Cl.C1C2=C(Cl)C=CC=C2N=C2N1[C@H](CC(C)C)C(=O)N2 HTXRKFKELTXNIG-UTONKHPSSA-N 0.000 description 1
- XYRHETICUQVAQZ-PFEQFJNWSA-N (3R)-6-chloro-3-phenyl-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one hydrochloride Chemical compound Cl.C1([C@@H]2C(=O)NC3=NC=4C=CC=C(C=4CN32)Cl)=CC=CC=C1 XYRHETICUQVAQZ-PFEQFJNWSA-N 0.000 description 1
- NBKJFQOLUSOWFF-ZCFIWIBFSA-N (3R)-7-bromo-3-methyl-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one Chemical compound C1C2=CC(Br)=CC=C2N=C2N1[C@H](C)C(=O)N2 NBKJFQOLUSOWFF-ZCFIWIBFSA-N 0.000 description 1
- LEJBIRAZTACNLU-QMMMGPOBSA-N (3S)-3,9-dimethyl-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one Chemical compound C1C2=CC=CC(C)=C2N=C2N1[C@@H](C)C(=O)N2 LEJBIRAZTACNLU-QMMMGPOBSA-N 0.000 description 1
- KBIKNIITOUTSLH-HNNXBMFYSA-N (3S)-3-benzyl-6-chloro-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one Chemical compound C(C1=CC=CC=C1)[C@H]1C(NC2=NC3=CC=CC(=C3CN21)Cl)=O KBIKNIITOUTSLH-HNNXBMFYSA-N 0.000 description 1
- RTJSPGKBNLTHJX-ZETCQYMHSA-N (3S)-3-methyl-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one Chemical compound C1C2=CC=CC=C2N=C2N1[C@@H](C)C(=O)N2 RTJSPGKBNLTHJX-ZETCQYMHSA-N 0.000 description 1
- FJWMBWBMHJYEHO-FJXQXJEOSA-N (3S)-3-methyl-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one hydrochloride Chemical compound Cl.C1C2=CC=CC=C2N=C2N1[C@@H](C)C(=O)N2 FJWMBWBMHJYEHO-FJXQXJEOSA-N 0.000 description 1
- XRKPMXZYDGSDPM-LBPRGKRZSA-N (3S)-6-chloro-3-(2-methylpropyl)-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one Chemical compound ClC1=C2CN3C(=NC2=CC=C1)NC([C@@H]3CC(C)C)=O XRKPMXZYDGSDPM-LBPRGKRZSA-N 0.000 description 1
- DPXGWUNFDLXCKS-AWEZNQCLSA-N (3S)-6-chloro-3-phenyl-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one Chemical compound ClC1=C2CN3C(=NC2=CC=C1)NC([C@@H]3C1=CC=CC=C1)=O DPXGWUNFDLXCKS-AWEZNQCLSA-N 0.000 description 1
- VLQPALBDGFYRBH-RGMNGODLSA-N (3S)-6-chloro-7-methoxy-3-methyl-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one hydrochloride Chemical compound Cl.ClC1=C2CN3C(=NC2=CC=C1OC)NC([C@@H]3C)=O VLQPALBDGFYRBH-RGMNGODLSA-N 0.000 description 1
- FHDHUOUALGSAIL-RGMNGODLSA-N (3S)-7-bromo-3-methyl-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one hydrochloride Chemical compound Cl.C1C2=CC(Br)=CC=C2N=C2N1[C@@H](C)C(=O)N2 FHDHUOUALGSAIL-RGMNGODLSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- DKOAMCBHOMXOPX-UHFFFAOYSA-N 1-(chloromethyl)-3-methyl-2-nitrobenzene Chemical compound CC1=CC=CC(CCl)=C1[N+]([O-])=O DKOAMCBHOMXOPX-UHFFFAOYSA-N 0.000 description 1
- MAIVNONTLACJOK-UHFFFAOYSA-N 2-(bromomethyl)-1-chloro-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(Cl)=C1CBr MAIVNONTLACJOK-UHFFFAOYSA-N 0.000 description 1
- FJWMBWBMHJYEHO-UHFFFAOYSA-N 3-methyl-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one hydrochloride Chemical compound Cl.C1=CC=C2NC3=NC(=O)C(C)N3CC2=C1 FJWMBWBMHJYEHO-UHFFFAOYSA-N 0.000 description 1
- WYQHLULFNFNASP-UHFFFAOYSA-N 3h-imidazo[2,1-b]quinazolin-2-one Chemical class C1=CC=CC2=NC3=NC(=O)CN3C=C21 WYQHLULFNFNASP-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- KOMRLUDDGJTIRU-RGMNGODLSA-N Cl.ClC1=C2CN3C(=NC2=CC=C1)NC([C@@H]3C)=O Chemical compound Cl.ClC1=C2CN3C(=NC2=CC=C1)NC([C@@H]3C)=O KOMRLUDDGJTIRU-RGMNGODLSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- TWZRQYVGCFXJLJ-UHFFFAOYSA-N acetic acid;1,4-dihydroquinazoline Chemical compound CC(O)=O.C1=CC=C2CN=CNC2=C1 TWZRQYVGCFXJLJ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001734 carboxylic acid salts Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- ZJYZQVSCSFKDPV-SNVBAGLBSA-N ethyl (2r)-2-[(2-amino-3-methylphenyl)methylamino]propanoate Chemical compound CCOC(=O)[C@@H](C)NCC1=CC=CC(C)=C1N ZJYZQVSCSFKDPV-SNVBAGLBSA-N 0.000 description 1
- AITNNCPPLYJMPW-SNVBAGLBSA-N ethyl (2r)-2-[(2-amino-5-methylphenyl)methylamino]propanoate Chemical compound CCOC(=O)[C@@H](C)NCC1=CC(C)=CC=C1N AITNNCPPLYJMPW-SNVBAGLBSA-N 0.000 description 1
- IHNPWXCCECFVGX-QGZVFWFLSA-N ethyl (2r)-2-[(2-amino-6-chlorophenyl)methylamino]-3-phenylpropanoate Chemical compound C([C@H](C(=O)OCC)NCC=1C(=CC=CC=1N)Cl)C1=CC=CC=C1 IHNPWXCCECFVGX-QGZVFWFLSA-N 0.000 description 1
- XTOYREDAYWBXOW-CQSZACIVSA-N ethyl (2r)-2-[(2-amino-6-chlorophenyl)methylamino]-4-methylpentanoate Chemical compound CCOC(=O)[C@@H](CC(C)C)NCC1=C(N)C=CC=C1Cl XTOYREDAYWBXOW-CQSZACIVSA-N 0.000 description 1
- JNKASCNGJPDNFK-SNVBAGLBSA-N ethyl (2r)-2-[(2-amino-6-methylphenyl)methylamino]propanoate Chemical compound CCOC(=O)[C@@H](C)NCC1=C(C)C=CC=C1N JNKASCNGJPDNFK-SNVBAGLBSA-N 0.000 description 1
- CSNSUUUPCIUOJV-SECBINFHSA-N ethyl (2r)-2-[(2-aminophenyl)methylamino]propanoate Chemical compound CCOC(=O)[C@@H](C)NCC1=CC=CC=C1N CSNSUUUPCIUOJV-SECBINFHSA-N 0.000 description 1
- QXGRINMHXDKSIY-SNVBAGLBSA-N ethyl (2r)-2-[(2-chloro-6-nitrophenyl)methylamino]-3-hydroxypropanoate Chemical compound CCOC(=O)[C@@H](CO)NCC1=C(Cl)C=CC=C1[N+]([O-])=O QXGRINMHXDKSIY-SNVBAGLBSA-N 0.000 description 1
- JICGZLATBHCWTA-MRXNPFEDSA-N ethyl (2r)-2-[(2-chloro-6-nitrophenyl)methylamino]-3-phenylpropanoate Chemical compound C([C@H](C(=O)OCC)NCC=1C(=CC=CC=1Cl)[N+]([O-])=O)C1=CC=CC=C1 JICGZLATBHCWTA-MRXNPFEDSA-N 0.000 description 1
- OSWAAOBYYDIABH-CYBMUJFWSA-N ethyl (2r)-2-[(2-chloro-6-nitrophenyl)methylamino]-4-methylpentanoate Chemical compound CCOC(=O)[C@@H](CC(C)C)NCC1=C(Cl)C=CC=C1[N+]([O-])=O OSWAAOBYYDIABH-CYBMUJFWSA-N 0.000 description 1
- ROBXZHNBBCHEIQ-SCSAIBSYSA-N ethyl (2r)-2-aminopropanoate Chemical compound CCOC(=O)[C@@H](C)N ROBXZHNBBCHEIQ-SCSAIBSYSA-N 0.000 description 1
- JCXLZWMDXJFOOI-PGMHMLKASA-N ethyl (2r)-2-aminopropanoate;hydrochloride Chemical compound Cl.CCOC(=O)[C@@H](C)N JCXLZWMDXJFOOI-PGMHMLKASA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- FVGAJEWYPIQRJX-UHFFFAOYSA-N imidazo[4,5-h]quinazolin-2-one Chemical class N1=CN=C2C3=NC(=O)N=C3C=CC2=C1 FVGAJEWYPIQRJX-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 239000011591 potassium Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000011734 sodium Chemical group 0.000 description 1
- 229910052708 sodium Chemical group 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU77829 | 1977-07-25 | ||
| LU77829 | 1977-07-25 | ||
| CH577678 | 1978-05-26 | ||
| CH577678 | 1978-05-26 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI782248A7 FI782248A7 (fi) | 1979-01-26 |
| FI63409B FI63409B (fi) | 1983-02-28 |
| FI63409C true FI63409C (fi) | 1983-06-10 |
Family
ID=25698353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI782248A FI63409C (fi) | 1977-07-25 | 1978-07-14 | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1,5-dihydro-imidazo(2,1-b)kinazolin-2(3h)-onderivat |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US4256748A (cs) |
| EP (1) | EP0000718B1 (cs) |
| JP (1) | JPS5441894A (cs) |
| AR (1) | AR218500A1 (cs) |
| AT (1) | AT363479B (cs) |
| AU (1) | AU519688B2 (cs) |
| BR (1) | BR7804763A (cs) |
| CA (1) | CA1094555A (cs) |
| CS (1) | CS203014B2 (cs) |
| DE (2) | DE2861688D1 (cs) |
| DK (1) | DK144128C (cs) |
| ES (2) | ES471981A1 (cs) |
| FI (1) | FI63409C (cs) |
| FR (1) | FR2398748A1 (cs) |
| GB (1) | GB2001638B (cs) |
| GR (1) | GR72968B (cs) |
| HU (1) | HU177643B (cs) |
| IE (1) | IE47280B1 (cs) |
| IL (1) | IL55183A (cs) |
| IT (1) | IT1097337B (cs) |
| MC (1) | MC1199A1 (cs) |
| MY (1) | MY8500249A (cs) |
| NL (1) | NL7807507A (cs) |
| NO (1) | NO150800C (cs) |
| NZ (1) | NZ187921A (cs) |
| PH (1) | PH14642A (cs) |
| PT (1) | PT68342A (cs) |
| SE (1) | SE7808111L (cs) |
| YU (1) | YU177578A (cs) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7807507A (nl) | 1977-07-25 | 1979-01-29 | Hoffmann La Roche | Tricyclische verbindingen. |
| US4146718A (en) * | 1978-04-10 | 1979-03-27 | Bristol-Myers Company | Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides |
| CA1131631A (en) * | 1979-06-20 | 1982-09-14 | Madhukar S. Chodnekar | Quinazoline derivatives and pharmaceutical preparations |
| EP0029559A3 (en) * | 1979-11-24 | 1981-09-30 | Sandoz Ag | 5,10-dihydroimidazo(2,1-b)quinazolines, their production and pharmaceutical compositions containing them |
| US4444768A (en) * | 1980-03-04 | 1984-04-24 | Ciba-Geigy Corporation | Pyrimido[1,6-a]indoles, pharmaceutical preparations containing them, and methods of treating pain and inflammation with them |
| ZW16481A1 (en) * | 1980-08-15 | 1982-03-10 | Hoffmann La Roche | Novel imidazoquinazoline derivatives |
| EP0054180A3 (de) * | 1980-12-16 | 1982-12-01 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Verfahren zur Herstellung eines Imidazochinazolinonderivates |
| JPS57178234U (cs) * | 1981-05-06 | 1982-11-11 | ||
| US4455311A (en) * | 1981-08-28 | 1984-06-19 | Hoffmann-La Roche Inc. | Imidazoquinazoline derivatives which inhibit the aggregation of blood platelets, inhibit gastric secretion or have activity on the circulatory system |
| US4663320A (en) * | 1983-02-16 | 1987-05-05 | Syntex (U.S.A.) Inc. | (2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinoazolinyl)oxyalkylamides, compositions and the use thereof |
| US4490371A (en) * | 1983-02-16 | 1984-12-25 | Syntex (U.S.A.) Inc. | N,N-Disubstituted-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl)oxyalkylamides |
| US4551459A (en) * | 1983-02-16 | 1985-11-05 | Syntex (U.S.A.) Inc. | Method of treating heart failure using (2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolinyl)oxyalkylamides |
| JPS604186A (ja) * | 1983-06-21 | 1985-01-10 | Dai Ichi Seiyaku Co Ltd | イミダゾキナゾリン化合物 |
| JPS6028979A (ja) * | 1983-07-14 | 1985-02-14 | Dai Ichi Seiyaku Co Ltd | イミダゾキナゾリン類化合物 |
| EP0153152A3 (en) * | 1984-02-15 | 1987-07-15 | Syntex (U.S.A.) Inc. | (2-oxo-1,2,3,5-tetrahydroimidazo-/2,1-b/quinnazolinyl)-oxyalkylamides, their preparation, compositions containing them and their use in making medicaments |
| GB8514207D0 (en) * | 1985-06-05 | 1985-07-10 | Pfizer Ltd | Cardiac stimulants |
| US4783467A (en) * | 1985-06-05 | 1988-11-08 | Pfizer Inc. | Tetrahydroimidazoquinazolinone inotropic agents |
| US4837239A (en) * | 1985-08-23 | 1989-06-06 | Syntex (U.S.A.) Inc. | Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins |
| US4670434A (en) * | 1985-11-14 | 1987-06-02 | Syntex (U.S.A.) Inc. | (2-oxo-3-methylene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolinyl)oxyalkylamides useful as cyclic AMP phosphodiesterase inhibitors |
| US4775674A (en) * | 1986-05-23 | 1988-10-04 | Bristol-Myers Company | Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors |
| US4701459A (en) * | 1986-07-08 | 1987-10-20 | Bristol-Myers Company | 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation |
| US5043327A (en) * | 1989-07-18 | 1991-08-27 | Janssen Pharmaceutica N.V. | Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives, compositions and use |
| US4943573A (en) * | 1989-11-01 | 1990-07-24 | Bristol-Myers Squibb Company | Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility |
| EP0597956A1 (en) * | 1991-07-29 | 1994-05-25 | Warner-Lambert Company | Quinazoline derivatives as acetylcholinesterase inhibitors |
| US5348960A (en) * | 1992-04-03 | 1994-09-20 | Bristol-Myers Squibb Company | Imidazo[4,5-b]quinolinyl oxy alkyl tetrazolyl piperidine derivatives |
| US5158958A (en) * | 1992-04-03 | 1992-10-27 | Bristol-Myers Squibb Company | Imidazo[4,5-b]quinolinyl oxy alkyl sulfonyl piperidine derivatives |
| US5196428A (en) * | 1992-04-03 | 1993-03-23 | Bristol-Myers Squibb Company | Imidazo[4,5-b]qinolinyl oxy alkyl ureas |
| US5208237A (en) * | 1992-04-03 | 1993-05-04 | Bristol-Meyers Squibb Company | 7-oxypropylsulfonamido-imidazo[4,5-b]quinolin-2-ones |
| JPH06167328A (ja) * | 1992-05-26 | 1994-06-14 | Mayekawa Mfg Co Ltd | 氷厚測定装置 |
| US6585995B1 (en) * | 1999-09-21 | 2003-07-01 | Hanson Stephen R | Methods and compositions for treating platelet-related disorders |
| US6388073B1 (en) * | 2000-07-26 | 2002-05-14 | Shire Us Inc. | Method for the manufacture of anagrelide |
| AP2103A (en) * | 2003-01-23 | 2010-02-08 | Shire Holdings Ag | A skin permeable form of an anagrelide and device therefore |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7700608B2 (en) | 2004-08-04 | 2010-04-20 | Shire Holdings Ag | Quinazoline derivatives and their use in the treatment of thrombocythemia |
| US20060030574A1 (en) * | 2004-08-04 | 2006-02-09 | Shire Holdings Ag | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors |
| US8436006B2 (en) * | 2004-08-06 | 2013-05-07 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
| US8426429B2 (en) | 2004-08-06 | 2013-04-23 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
| US8383637B2 (en) | 2004-08-06 | 2013-02-26 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
| GB0623750D0 (en) * | 2006-11-28 | 2007-01-10 | Shire Llc | Substituted quinazolines |
| US8304420B2 (en) | 2006-11-28 | 2012-11-06 | Shire Llc | Substituted quinazolines for reducing platelet count |
| US7910597B2 (en) * | 2006-11-28 | 2011-03-22 | Shire Llc | Substituted quinazolines |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| ES2559319T3 (es) | 2007-06-04 | 2016-02-11 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| GB0808950D0 (en) * | 2008-05-16 | 2008-06-25 | Shire Llc | Substituted quinazolines |
| GB0808952D0 (en) * | 2008-05-16 | 2008-06-25 | Shire Llc | Substituted quinazolines |
| GB0808944D0 (en) * | 2008-05-16 | 2008-06-25 | Shire Llc | Substituted quinazolines |
| GB0808953D0 (en) * | 2008-05-16 | 2008-06-25 | Shire Llc | substituted quinazolines |
| GB0808951D0 (en) * | 2008-05-16 | 2008-06-25 | Shire Llc | Substituted quinazolines |
| GB0808968D0 (en) * | 2008-05-16 | 2008-06-25 | Shire Llc | Substitute quinazolines |
| GB0808948D0 (en) * | 2008-05-16 | 2008-06-25 | Shire Llc | Substituted quinazolines |
| GB0808967D0 (en) * | 2008-05-16 | 2008-06-25 | Shire Llc | Substitute quinazolines |
| GB0808947D0 (en) * | 2008-05-16 | 2008-06-25 | Shire Llc | Substituted quinazolines |
| GB0810005D0 (en) * | 2008-06-02 | 2008-07-09 | Shire Llc | Substituted quinazolines |
| WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| GB0822970D0 (en) | 2008-12-17 | 2009-01-21 | Shire Llc | Process for the preparation of anagrelide and analogues |
| GB201004495D0 (en) | 2010-03-18 | 2010-05-05 | Shire Llc | Subtituted quinazolines |
| GB201004491D0 (en) | 2010-03-18 | 2010-05-05 | Shire Llc | Quinazoline analogues |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CA2828346C (en) | 2011-03-01 | 2021-01-26 | Synergy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
| CA2902348C (en) | 2013-02-25 | 2021-11-30 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| HK1220611A1 (zh) | 2013-03-15 | 2017-05-12 | Bausch Health Ireland Limited | 用於治疗胃肠道病症的组成物 |
| SI3004138T1 (sl) | 2013-06-05 | 2024-07-31 | Bausch Health Ireland Limited | Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo |
| CN114404588A (zh) | 2013-08-09 | 2022-04-29 | 阿德利克斯公司 | 用于抑制磷酸盐转运的化合物和方法 |
| JP5935843B2 (ja) * | 2014-08-08 | 2016-06-15 | Ｊｆｅスチール株式会社 | スポット溶接性に優れた冷延鋼板およびその製造方法 |
| US20200368223A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Methods for inhibiting phosphate transport |
| EP4201403A1 (en) | 2021-12-21 | 2023-06-28 | Som Innovation Biotech, S.L. | Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1445430A1 (de) | 1962-10-26 | 1969-01-23 | American Home Prod | Verfahren zur Herstellung von 3-Acyloxy-1,3-dihydro-2 H-1-benzodiazepin-2-onen |
| GB1037375A (en) * | 1964-08-07 | 1966-07-27 | Hoffmann La Roche | A process for the manufacture of benzodiazepine derivatives |
| US3932407A (en) * | 1973-11-19 | 1976-01-13 | Bristol-Myers Company | Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones |
| BE794964A (fr) | 1972-02-04 | 1973-08-02 | Bristol Myers Co | Nouveaux agents hypotenseurs et procede pour les preparer |
| US3983119A (en) * | 1974-11-06 | 1976-09-28 | Bristol-Myers Company | Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones |
| US3988340A (en) * | 1975-01-23 | 1976-10-26 | Bristol-Myers Company | 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones |
| NL7807507A (nl) | 1977-07-25 | 1979-01-29 | Hoffmann La Roche | Tricyclische verbindingen. |
-
1978
- 1978-07-12 NL NL7807507A patent/NL7807507A/xx not_active Application Discontinuation
- 1978-07-13 MC MC781312A patent/MC1199A1/xx unknown
- 1978-07-14 FI FI782248A patent/FI63409C/fi not_active IP Right Cessation
- 1978-07-18 AU AU38127/78A patent/AU519688B2/en not_active Expired
- 1978-07-19 FR FR7821396A patent/FR2398748A1/fr active Granted
- 1978-07-19 HU HU78HO2088A patent/HU177643B/hu unknown
- 1978-07-20 IL IL55183A patent/IL55183A/xx unknown
- 1978-07-20 NZ NZ187921A patent/NZ187921A/xx unknown
- 1978-07-20 CA CA307,767A patent/CA1094555A/en not_active Expired
- 1978-07-21 EP EP78100471A patent/EP0000718B1/de not_active Expired
- 1978-07-21 DE DE7878100471T patent/DE2861688D1/de not_active Expired
- 1978-07-21 PH PH21412A patent/PH14642A/en unknown
- 1978-07-21 DE DE19782832138 patent/DE2832138A1/de not_active Withdrawn
- 1978-07-24 JP JP8953478A patent/JPS5441894A/ja active Pending
- 1978-07-24 NO NO782541A patent/NO150800C/no unknown
- 1978-07-24 SE SE7808111A patent/SE7808111L/xx unknown
- 1978-07-24 PT PT68342A patent/PT68342A/pt unknown
- 1978-07-24 BR BR7804763A patent/BR7804763A/pt unknown
- 1978-07-24 GB GB787830868A patent/GB2001638B/en not_active Expired
- 1978-07-24 DK DK328978A patent/DK144128C/da not_active IP Right Cessation
- 1978-07-24 IE IE1478/78A patent/IE47280B1/en unknown
- 1978-07-24 GR GR56847A patent/GR72968B/el unknown
- 1978-07-24 IT IT26019/78A patent/IT1097337B/it active
- 1978-07-24 AT AT0535178A patent/AT363479B/de active
- 1978-07-24 CS CS784914A patent/CS203014B2/cs unknown
- 1978-07-24 ES ES471981A patent/ES471981A1/es not_active Expired
- 1978-07-25 AR AR273064A patent/AR218500A1/es active
- 1978-07-25 YU YU01775/78A patent/YU177578A/xx unknown
-
1979
- 1979-01-18 ES ES476955A patent/ES476955A1/es not_active Expired
- 1979-06-20 US US06/050,395 patent/US4256748A/en not_active Expired - Lifetime
-
1985
- 1985-12-30 MY MY249/85A patent/MY8500249A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI63409C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1,5-dihydro-imidazo(2,1-b)kinazolin-2(3h)-onderivat | |
| JP6779214B2 (ja) | Ｒｏｃｋ阻害剤としての環状ウレア | |
| AU781826B2 (en) | Tricycle inhibitors of poly(ADP-ribose) polymerases | |
| JP3026020B2 (ja) | ３環性プテリジノン類及びその製造方法 | |
| FI82464B (fi) | Foerfarande foer framstaellning av bensoxazepinderivat med laekemedelsverkan. | |
| DK164704B (da) | 3,6-disubstituerede triazolo-oe3,4-aaa-ftalazinderivater, fremgangsmaade til fremstilling deraf, udgangsforbindelse til anvendelse i fremgangsmaaden samt anvendelse af og farmaceutisk praeparat indeholdende forbindelserne | |
| KR20210011925A (ko) | Stat3 억제제 | |
| US20090082565A1 (en) | Methods of preparing quinolone analogs | |
| HU197749B (en) | Process for producing /3,4-d/pyrimidine derivatives and pharmaceutical compositions comprising these compounds as active ingredient | |
| US5728709A (en) | Alkyl and aralkyl-substituted pyrrolocarbazole derivatives that stimulate platelet production | |
| JPWO2005095389A1 (ja) | 複素環式化合物及びそれを有効成分とする抗悪性腫瘍剤 | |
| EP0743942A1 (en) | 5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists | |
| NL8002610A (nl) | Heterocyclische verbindingen en werkwijzen voor het bereiden en toepassen van deze verbindingen. | |
| CN110028521B (zh) | 11-芳基-1,4-苯并恶嗪酮并咪唑啉类化合物及其制备方法和用途 | |
| JPH0730088B2 (ja) | 置換アゼチジニルイソチアゾロピリドン誘導体、その製造法及びその医薬用途 | |
| Lee et al. | Antitumor agents. 86. Synthesis and cytotoxicity of. alpha.-methylene-. gamma.-lactone-bearing purines | |
| JPH0377881A (ja) | ニコチン酸アミド化合物 | |
| Temple et al. | Pyrimido [5, 4-e]-as-triazines. VII. Synthesis of 7-aza analogs of pteroic and folic acids | |
| Dalla Croce et al. | Reactions of hydrazonoyl halides with imidazoles and benzimidazoles | |
| Birnberg et al. | The synthesis of 5‐arylpyrrolo [3, 2‐b] pyridines and 7‐arylpyrrolo [3, 2‐b] pyridines: Addition of 3‐aminopyrroles to aryl enaminones | |
| PT86154B (pt) | Processo para a preparacao de novos pirrolobenzimidazoles e de composicoes farmaceuticas que os contem | |
| US20040180898A1 (en) | Processes for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines | |
| US5302722A (en) | 3-carboxy-pyrrole derivatives | |
| CN117003734A (zh) | 嘧啶并环类衍生物及其制备方法和用途 | |
| US3737434A (en) | Certain2-acyl-2,4-dihydro-6-phenyl(1,2,3,5)thiatriazolo(5,4-a)(1,4)benzodiazepine-1-oxides and process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: F. HOFFMANN-LA ROCHE & CO. |